Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Multivariable analysis of PFS

From: Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab

Parameter Hazard Ratio 95% Confidence Interval p-value
Baseline Lung Metastases 1.92 0.96, 3.86 0.066
Baseline LN Metastases 1.67 0.88, 3.19 0.12
Baseline Pleural Metastases 1.69 0.86, 3.33 0.1
IMDC Intermediate Risk Group (Favorable as reference) 0.62 0.25, 1.56 0.31
IMDC Poor Risk Group (Favorable as reference) 0.51 0.16, 1.66 0.26
Baseline Neutrophil to Lymphocyte Ratio (NLR) < 4.2 vs > = 4.2 1.86 1.05, 3.29 0.033
Baseline Absolute Eosinophil Count (k/uL) < 0.1 vs > = 0.1 0.54 0.30, 0.98 0.042